We are pleased to announce we have appointed Michael Cooper as American Rheumatology Network’s (ARN) new CEO, effective immediately.
Michael’s appointment reflects ARN’s current state: enthusiastic and ready to take on the future after another strong year of growth and success. We are excited for Michael to guide our company using his unique experience in distribution and group purchasing organizations. There is enormous opportunity for ARN that lies ahead, and we could not be happier with Michael joining our family and helping our network achieve continued success.
Michael is an effective healthcare executive with over 30 years of experience as a healthcare provider, as a distribution and GPO healthcare partner, and as a trusted resource to pharmaceutical organizations. He has delivered value at the highest levels to his customers and has developed a rich network of trusted colleagues and partners in the Specialty Market. Michael is gifted in understanding core issues and in developing unique solutions to drive access and utilization. Further, Michael has assisted multiple financial entities by providing insightful feedback pertinent to different healthcare models.
Ray Waldrup, our former CEO of ARN, will continue to serve as Chief Development Officer of ARN. Ray was one of the first to see the significant potential of developing a rheumatology network and is responsible for the rapid growth of the company that we have seen in the past two years. We cannot thank him enough for his leadership and contributions. To us, he is a true pioneer and visionary, and we are happy he will continue to work alongside our management team.
Please join us in welcoming Michael to the Network team!